Johnson Winter & Slattery has advised its long standing client, Blackmores, on its divestment in Global Therapeutics.
Blackmores sold Global Therapeutics to McPherson (whose portfolio of brands includes Manicare, Lady Jayne, Dr. LeWinn’s, A'kin, Swisspers, Multix, Moosehead and Maseur) at an enterprise value of $27 million.
Under the deal, McPherson will acquire Blackmore’s Fusion Health and Oriental Botanical brands, which has a product range that draws upon traditional Chinese medicine in combination with contemporary herbal treatments.
The Johnson Winter & Slattery team was led by Partner Jeremy Davis, alongside Senior Associate Isabella Bosworth, and Associates Will Mason and Rebecca Proudman. Partner Ravi de Fonseka advised on the IP / IT aspects of this transaction and Prashanth Kainthaje advised on the tax aspects.
Jeremy Davis said the firm was delighted to have supported Blackmores on this strategic divestment.
“The sale of Global Therapeutics closely follows Blackmore’s announcement that it would be divesting in all non-core brands in its portfolio. This transaction will enable Blackmores to focus on its core business, while at the same time giving Global Therapeutics the opportunity to grow under McPherson."
Thompson Geer advised McPherson on this transaction.
About Johnson Winter & Slattery
Johnson Winter & Slattery is an independent national Australian law firm with over 65 partners and offices across Australia. We advise major Australian and international corporations and investment funds on their most challenging transactions and disputes across Australia and surrounding regions. Working closely with clients, knowing their business, and appreciating their commercial objectives, we tailor our approach to deliver cost-effective commercial outcomes.
Daya Knapton, Communications Manager
T: +61 2 8247 9638
Kate Potter, Marketing & Business Development Director
T: +61 2 8247 9659
Be the first to receive the latest articles, news and publications.